SERVICES

Archive | Drugs and Pharmaceuticals

EPEIUS

Rexin-G Returns to The Big Apple: Clinical Trials for Pancreatic Cancer and Breast Cancer Open in Manhattan

SAN MARINO, Calif., Oct. 29 (SEND2PRESS NEWSWIRE) — Epeius Biotechnologies Corporation announced today the expansion of clinical trials using intravenous Rexin-G for pancreatic cancer and breast cancer in Manhattan, New York. Rexin-G is the world’s first tumor-targeted genetic medicine that is designed to seek out and destroy both primary tumors and metastatic cancers that have […]

Continue Reading

SELECT TRIAL used Selenomethionine Instead of High-Selenium Yeast, SelenoExcell(R)

FRESNO, Calif., Oct. 29 (SEND2PRESS NEWSWIRE) — Cypress Systems, Inc, a Fresno CA based biotechnology company, emphasizes that the SELECT TRIAL results – that were announced yesterday – used a form of selenium known as selenomethionine. The SELECT TRIAL found no effects of either selenomethionine or vitamin E on the incidence of prostate cancer. See […]

Continue Reading
Epeius

Epeius Biotechnologies’ Tumor-Targeted Rexin-G Receives FDA Orphan Drug Designation for The Treatment of Osteosarcoma

SAN MARINO, Calif., July 8 (SEND2PRESS NEWSWIRE) — Epeius Biotechnologies Corporation today announced that Rexin-G has been granted Orphan Drug Designation by the U.S. Food and Drug Administration (FDA) for the treatment of osteosarcoma. Based on several criteria, including the rarity, seriousness, and current lack of effective therapies for metastatic osteosarcoma, as well as the […]

Continue Reading
Caption: Epeius

ASCO 2008: Tumor-Targeted Rexin-G Demonstrates Dose-Dependent Anti-Tumor Activity without Toxicity in Metastatic Pancreatic Cancer

SAN MARINO, Calif., May 19 (SEND2PRESS NEWSWIRE) — Epeius Biotechnologies announced today the results of an on-going Phase I/II study of Rexin-G for metastatic pancreatic cancer (Chawla et al., ASCO meeting, 2008). Continuing on with the planned dose-escalations of Rexin-G which began in 2005 using lower doses of Rexin-G in a Phase I safety study […]

Continue Reading
Caption: Dr. Andree Bates, president of Eularis

Eularis to Address Marketing Return at Japanese Pharmaceutical Marketing Excellence Conference

TOKYO and LONDON, U.K., May 12 (SEND2PRESS NEWSWIRE) — Dr. Andree Bates, president of the New York and London-based pharmaceutical analytics company Eularis, will be delivering a presentation on how to tell if you are making the wrong marketing decision. The Pharmaceutical Marketing Excellence conference takes place in Tokyo, Japan.

Continue Reading
Caption: Dr. Mark E. Whitacre

Cypress Systems, Inc. Launches Cancer Prevention Health Campaign Using SelenoExcell(R)

FRESNO, Calif., April 15 (SEND2PRESS NEWSWIRE) — Chairman and CEO, Paul Willis stated, ‘Just like his previous career at a large agribusiness company, Dr. Mark E. Whitacre has risen fast at Cypress Systems, Inc, last month being named the company’s chief operating officer and president of operations.’ Now Cypress and Whitacre are focusing their energy […]

Continue Reading
Caption: Mark Whitacre

Mark Whitacre, Ph.D. Promoted at Cypress Systems, Inc. and a Warner Bros. Movie to be Filmed About Him

FRESNO, Calif., March 25 (SEND2PRESS NEWSWIRE) — Cypress Systems, Inc., a Fresno CA based biotechnology company, announced that it has promoted Mark E. Whitacre, Ph.D. to become the company’s Chief Operating Officer (COO) and President of Operations. Dr. Whitacre joined the executive management team in December 2006 as President of Technology and Business Development for […]

Continue Reading

deverus, Inc. Partners with eScreen Inc. to Offer First and Only Instrumented Instant Drug Testing Device to Clients

AUSTIN, Texas – Jan. 4 (SEND2PRESS NEWSWIRE) — deverus, Inc., the leader in background screening technology, recently announced a partnership with eScreen Inc., a company known for its innovative drug screening technology. After comparing different providers, deverus found that no one could match the selection and quality of products that eScreen had to offer. Through […]

Continue Reading
(c) Send2Press

Ophthalmic Research and Development Company Launches Adjunctive Eyelid Therapy and Hygiene Product

RICHMOND, Texas – Aug. 6 (SEND2PRESS NEWSWIRE) — CYNACON /OCuSOFT(R) (OCuSOFT, Inc.) specializes in ophthalmic research, development and supply to ophthalmologists and optometrists. They are excited to announce a new and innovative prescription-only ALODOX(R) Convenience Kit for adjunctive eyelid therapy and hygiene.

Continue Reading

Part of the Neotrope® News Network, USA. Neotrope.net